MOU to Process Glencore's Feedstock 'Positive Step' for Cobalt Firm's Refinery
Source: Streetwise Reports 05/27/2019
The terms and implications of the arrangement are reviewed in a Canaccord Genuity report.
In a May 21 research note, Canaccord Genuity analyst Eric Zaunscherb reported that First Cobalt Corp. (FCC:TSX.V; FTSSF:OTCQX; FCC:ASX) signed a memorandum of understanding (MOU) with Glencore to process, at First Cobalt’s refinery in Ontario, feedstock supplied by Glencore. “We see this MOU as a positive step for the company,” Zaunscherb added.
The refinery, the only permitted primary cobalt refinery in North America, is not currently operating, and First Cobalt has not made a final decision yet to restart it. However, Glencore, per the MOU, will consider making a loan to fund the capital requirements to recommission the refinery and enter into a tolling agreement with First Cobalt.
The two companies will collaborate on the final flowsheet design, and the refinery could be back in operation in 18–24 months. Glencore’s contributed feedstock would generate about 2,000–2,500 tons per annum of cobalt sulfate from the refinery.
First Cobalt is working with the provincial government as well to possibly streamline and accelerate the permit amendment process.
The energy firm views the refinery opportunity as a way to generate cash flow in the near term as it continues advancing its Iron Creek project in Idaho and its project in Cobalt, Ontario.
Potential catalysts for First Cobalt are further clarity around derisking of the refinery and additional exploration results from Iron Creek.
Canaccord Genuity has a Speculative Buy rating and a CA$0.70 per share price target on First Cobalt; the stock is currently trading at around CA$0.16 per share.
Sign up for our FREE newsletter at: www.streetwisereports.com/get-news
Disclosure:
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports’ terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
Disclosures from Canaccord Genuity, First Cobalt, Flash Update, May 21, 2019
Analyst Certification: Each authoring analyst of Canaccord Genuity whose name appears on the front page of this research hereby certifies that (i) the recommendations and opinions expressed in this research accurately reflect the authoring analyst’s personal, independent and objective views about any and all of the designated investments or relevant issuers discussed herein that are within such authoring analyst’s coverage universe and (ii) no part of the authoring analyst’s compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed by the authoring analyst in the research.
Analysts employed outside the US are not registered as research analysts with FINRA. These analysts may not be associated persons of Canaccord Genuity Inc. and therefore may not be subject to the FINRA Rule 2241 and NYSE Rule 472 restrictions on communications with a subject company, public appearances and trading securities held by a research analyst account.
The authoring analysts who are responsible for the preparation of this research have received (or will receive) compensation based upon (among other factors) the Investment Banking revenues and general profits of Canaccord Genuity. However, such authoring analysts have not received, and will not receive, compensation that is directly based upon or linked to one or more specific Investment Banking activities, or to recommendations contained in the research.
Canaccord Genuity or one or more of its affiliated companies intend to seek or expect to receive compensation for Investment Banking services from First Cobalt Corp. in the next three months.
The primary analyst, a member of primary analyst’s household, or any individual directly involved in the preparation of this research, has a long position in the shares or derivatives, or has any other financial interest in First Cobalt Corp., the value of which increases as the value of the underlying equity increases.
An analyst has visited the material operations of First Cobalt Corp. Partial payment was received for the related travel costs.
Disclosures are available here.
( Companies Mentioned: FCC:TSX.V; FTSSF:OTCQX; FCC:ASX, )
Source: https://www.streetwisereports.com/article/2019/05/27/mou-to-process-glencores-feedstock-positive-step-for-cobalt-firms-refinery.html
Anyone can join.
Anyone can contribute.
Anyone can become informed about their world.
"United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.
Before It’s News® is a community of individuals who report on what’s going on around them, from all around the world. Anyone can join. Anyone can contribute. Anyone can become informed about their world. "United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.
LION'S MANE PRODUCT
Try Our Lion’s Mane WHOLE MIND Nootropic Blend 60 Capsules
Mushrooms are having a moment. One fabulous fungus in particular, lion’s mane, may help improve memory, depression and anxiety symptoms. They are also an excellent source of nutrients that show promise as a therapy for dementia, and other neurodegenerative diseases. If you’re living with anxiety or depression, you may be curious about all the therapy options out there — including the natural ones.Our Lion’s Mane WHOLE MIND Nootropic Blend has been formulated to utilize the potency of Lion’s mane but also include the benefits of four other Highly Beneficial Mushrooms. Synergistically, they work together to Build your health through improving cognitive function and immunity regardless of your age. Our Nootropic not only improves your Cognitive Function and Activates your Immune System, but it benefits growth of Essential Gut Flora, further enhancing your Vitality.
Our Formula includes: Lion’s Mane Mushrooms which Increase Brain Power through nerve growth, lessen anxiety, reduce depression, and improve concentration. Its an excellent adaptogen, promotes sleep and improves immunity. Shiitake Mushrooms which Fight cancer cells and infectious disease, boost the immune system, promotes brain function, and serves as a source of B vitamins. Maitake Mushrooms which regulate blood sugar levels of diabetics, reduce hypertension and boosts the immune system. Reishi Mushrooms which Fight inflammation, liver disease, fatigue, tumor growth and cancer. They Improve skin disorders and soothes digestive problems, stomach ulcers and leaky gut syndrome. Chaga Mushrooms which have anti-aging effects, boost immune function, improve stamina and athletic performance, even act as a natural aphrodisiac, fighting diabetes and improving liver function. Try Our Lion’s Mane WHOLE MIND Nootropic Blend 60 Capsules Today. Be 100% Satisfied or Receive a Full Money Back Guarantee. Order Yours Today by Following This Link.